Zach Hill
Chief Technology Officer Montara Therapeutics
Seminars
Thursday 29th October 2026
BrainTACs Enable Brain-Selective Inhibition of CNS Targets, with Reduced Peripheral Adverse Effects
11:45 am
- Overview Montara’s BrainOnly™ platform and how our two-drug combinations enable brain-selective pharmacology through spatially restricted induced proximity
- Detail progress on our lead asset, MTX-E1, for brain-selective mTOR inhibition
- Provide insight into expanding the platform to additional targets and indications using our heterobifunctional BrainTACs™ (Brain Targeting Chimeras) for brain-selective two-drug combinations
